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Edited by Felix WielandAbstract We investigated the role of the stop transfer sequence of
human UGT1A6 in ER assembly and enzyme activity. We found
that this sequencewas able to address and translocate the upstream
lumenal domain into microsomal membranes in vitro co- and post-
translationally. The signal activity of this sequence was further
demonstrated in HeLa cells by its ability to target and maintain
the CD4 protein deleted from both the N-terminal signal peptide
and C-terminal transmembrane domain into the ER. We showed
that total or partial deletion of the stop transfer sequence of
UGT1A6 severely impaired enzyme activity highlighting its
importance in both membrane assembly and function.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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protein1. Introduction
Biosynthesis of integral membrane proteins involves several
events such as targeting to the endoplasmic reticulum (ER),
translocation of certain domains into the ER lumen and inte-
gration of transmembrane domains (TMDs) into the lipid
bilayer. In mammalian cells, protein targeting and transloca-
tion to the ER is mostly cotranslational, i.e., protein transloca-
tion and membrane insertion are coupled to protein synthesis
[1]. Most of the proteins destined for the ER contain a signal
sequence at or near the N-terminus, which is necessary for tar-
geting and translocation. Posttranslational targeting and mem-
brane insertion have been shown also for mammalian proteins
such as ‘‘tail anchored’’ proteins, since the C-terminal anchor-
ing domain emerges from the ribosome only after translation
has reached the stop codon [2]. In the case of polytopic pro-
teins, it has been shown that internal TMDs function as ER
targeting signal. This implies that a portion of the protein up-
stream of the TMD translocates posttranslationally [3].
Human UDP-glucuronosyltransferase 1A6 (UGT1A6) is a
member of UGT superfamily, which plays a key role in theAbbreviations: CT, cytosolic tail; ER, endoplasmic reticulum; TMD,
transmembrane domain; UGT, UDP-glucuronosyltransferase
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conjugation to glucuronic acid from the donor substrate,
UDP-glucuronic acid [4]. UGTs are predicted to be type I
membrane proteins of the ER with a glycosylated lumenal do-
main. They contain a stop transfer sequence at the C-terminus
consisting of 17 residues-TMD followed by a short cytoplas-
mic tail (CT) of 25 residues. We previously showed that
UGT1A6 contains an internal topogenic signal domain located
in the 140–240 region which interacts with the ER membrane
[5], suggesting that the membrane organization of UGT1A6
is more complex than a typical type I membrane protein. In
this study, we brought evidence that UGT1A6 stop transfer se-
quence presented ER targeting and translocation signal activ-
ities. This topogenic determinant in association with the
internal and the N-terminal signal peptides may cooperate to
achieve the ER membrane organization of the protein.2. Materials and methods
2.1. Plasmid constructions
The UGT1A6DN240 sequence coding for human UGT1A6 deleted
from 240 N-terminal residues and the UGT1A6DN240DTMD/CT se-
quence coding for UGT1A6 deleted from both 240 N-terminal residues
and the stop transfer sequence (TMD/CT, 43 C-terminal residues) were
generated by PCR. Brieﬂy, two oligonucleotide primers were used in a
PCR reaction with UGT1A6 cDNA as template, the 5 0 primer contain-
ing an ATG initiation codon in Kozak sequence followed by nucleo-
tides 720–737 of UGT1A6 cDNA and the 3 0 primer consisting of
nucleotides 1576–1593 followed by a stop codon in the case of UG-
T1A6DN240 and nucleotides 1551–1534 followed by a stop codon in
the case of UGT1A6DN240DTMD/CT. The PCR products were
subcloned into SmaI site of pGEM-3Z (Promega) under the control
of T7 promoter to generate pGEM-UGT1A6DN240 and pGE-
MUGT1A6DN240DTMD/CT. The recombinant plasmids were then
used for in vitro transcription/translation in rabbit reticulocyte lysate
using T7 RNA polymerase (Promega).
To generate the pCD4-TMD/CT vector expressing CD4 ectodomain
sequence (encoding for CD4 lumenal domain containing the N-terminal
signal peptide but lacking the C-terminal transmembrane and the cyto-
solic domains), in fusion with TMD/CT of UGT1A6, coding sequence
for TMD/CT was ampliﬁed by PCR using UGT1A6 cDNA as template
and two primers, a 5 0 primer A (5 0GGATCCGTGATTGGTT-
TCCTCTTG3 0) containing a BamHI site and UGT1A6 nucleotides
1467–1482 and a 3 0 primer B (5 0CTCGAGTCAATGGGTCT-
TGGATTTGTG3 0) encoding the last six residues of human UGT1A6
(1593–1576) followed by a stop codon and XhoI site. The PCR product
was cloned into BamHI and XhoI sites of pTM1 expression vector in
frame with CD4 ectodomain.
To generate pDPSCD4-TMD/CT vector, DPSCD4-TMD/CT se-
quence expressing CD4 ectodomain deleted from the N-terminal signal
peptide (lumenal domain) and fused with UGT1A6 TMD/CT wasblished by Elsevier B.V. All rights reserved.
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mer C (5 0GAATTCCACCATGAAGAAAGTGGTGCTGGGCAA3 0)
containing a EcoRI site, a Kozak sequence and nucleotides 76–95 corre-
sponding to CD4 coding region and oligonucleotide B (above) as 3 0 pri-
mer. The PCR product was cloned into EcoRI and XhoI sites of
pCDNA3.1 expression vector to generate pDPSCD4-TMD/CT vector.
Recombinant yeast vector pPICZ-UGT1A6 expressing full-length
UGT1A6 has been reported [6]. pPICZ-UGT1A6DCT and pPICZ-
UGT16DTMD/CT expressing UGT1A6 deleted from the CT or from
TMD/CT were constructed as follows: UGT1A6DCT and
UGT16DTMD/CT sequences were ampliﬁed by PCR using UGT1A6
cDNA as template and a 5 0 primer containing EcoRI site, a Kozak se-
quence and nucleotides 1–22 of UGT1A6 coding sequence in combina-
tion with a 3 0 primer comprising XbaI site, a stop codon and
nucleotides 1515–1498 in the case of UGT1A6DCT and a 3 0 primer
comprising XbaI site, a stop codon, and nucleotides 1464–1449 in
the case of UGT1A6DTMD/CT. The PCR products were inserted into
EcoRI–XbaI sites of pPICZB vector.
Mutation of asparagine residues of the N-glycosylation consensus
sites at positions 293 and 345 of UGT1A6 to glycine was performed
using QuickChange mutagenesis kit and appropriate primers (Strata-
gene, La Jolla, CA).
2.2. In vitro transcription/translation
Following linearization, the plasmids pGEM-UGT1A6DN240 and
pGEMUGT1A6 DN240DTMD/CT served as templates for in vitro
transcription by T7 RNA polymerase using mCAP RNA capping kit
(Stratagene). RNA products were translated in vitro using [35S] radi-
olabeled methionine and rabbit reticulocyte lysate cell-free translation
system in the presence or absence of canine pancreatic microsomal
membranes according to the supplier’s instructions (Promega). Alka-
line extraction of microsomal membrane proteins followed by subfrac-
tionation was performed as previously described [5,7]. EndoH
treatment of the translation products was performed as described by
Chen-Levy and Cleary [8]. For posttranslational membrane process-
ing, after 30 min translation, 2 mM cycloheximide was added for
10 min to inhibit further polypeptide chain elongation and transloca-
tion process was then initiated by addition of microsomal membranes.
The incubation was continued for 30 min at 30 C [5].
2.3. Immunoﬂuorescence microscopy and enzyme activity
Immunoﬂuorescence was carried out as previously described [9]. Re-
combinant expression of wild-type and UGT1A6 mutants in yeast P.
pastoris was performed as described by Ouzzine et al. [6]. The enzyme
activity was evaluated by incubation of microsomal proteins (30 lg)
with 1-naphthol or tetrachlorocatechol (1 mM) in presence of
0.1 mM UDP-glucuronic acid (0.1 lCi UDP-[U-14C]-glucuronic acid)
for 1 h followed by separation of the radiolabeled glucuronide by thin
layer chromatography [10].3. Results
3.1. The stop transfer sequence of UGT1A6 acts as a membrane
targeting signal peptide sequence
In order to investigate the topogenic role of UGT1A6 stop
transfer sequence, two UGT1A6 deletion mutants, UG-
T1A6DN240DTMD/CT and UGT1A6DN240, were expressed
in an in vitro transcription/translation system supplemented or
not with pancreatic ER-derived microsomes (see Fig. 1B).
Translocation and insertionof the polypeptides intomicrosomal
membranes were characterized by their glycosylation pattern
and resistance to alkaline treatment. Translation of UG-
T1A6DN240DTMD/CT in the absence of microsomes yielded
a polypeptide of about 26 kDa (see Fig. 1B, lane a). A polypep-
tide band of a similar size was obtained in the presence of micro-
somes (see Fig. 1B, lane b), suggesting that the N-linked glycan
attachment sites were not processed. Indeed, EndoH did not
produce any change in the apparent mass of the polypeptide
indicating that no glycosylation occurred (see Fig. 1B, lane e).In addition, most of UGT1A6DN240DTMD/CT polypeptide
was recovered in the soluble fraction after alkaline treatment
indicating that it was not integrated to the membranes (see
Fig. 1B, compare lanes d and c).Altogether, these results demon-
strated that UGT1A6DN240DTMD/CT polypeptide does not
contain any topogenic determinant for targeting, translocation
or membrane insertion.
In the case of UGT1A6DN240, translation in the absence of
microsomal membranes resulted in a band of about 30 kDa
(see Fig. 1B, lane f) corresponding to the expected apparent
molecular mass of unglycosylated polypeptide. In the presence
of microsomes, a polypeptide band exhibiting a slower mobility
(32 kDa) was generated (see Fig. 1B, lane g). The increase in
apparent molecular mass was consistent with glycosylation, as
EndoH treatment shifted the mobility of the polypeptide by
about 2 kDa (see Fig. 1B, compare lanes g and j). This indicated
that the polypeptide was exposed to the lumen of the micro-
somes and glycosylated. It is noteworthy that UGT1A6 protein
contains two potential glycosylation sites at positions 293 and
345. Disruption of N-linked glycosylation consensus sequences
at positions 293 and 345 by site-directed mutagenesis of aspara-
gine to glycine and treatment ofmutant proteins byEndoH indi-
cated that only the site at position 345 was glycosylated (see
Fig. 1C). Indeed, mutation of asparagine 345 to glycine pro-
duced a shift of about 2 kDa and resulted in resistance to EndoH
treatment whereas mutation of asparagine 293 had no eﬀect on
either mobility of the polypeptide or on sensitivity to EndoH
treatment. These results are consistent with the shift of 2 kDa
observed in in vitro experiments described above.Alkaline treat-
ment of microsomes followed by subfractionation showed that
the 32 kDa polypeptide was recovered in the microsomal frac-
tion and therefore tightly integrated into the lipid bilayer of
the membranes (see Fig. 1B, compare lanes h and i).3.2. UGT1A6 stop transfer sequence targeting and integration
into the ER can occur posttranslationally
The C-terminal position of the stop transfer sequence sug-
gests that it emerges from the ribosome only upon termination
of translation. Therefore, it is unlikely that it interacts with the
membranes before the polypeptide has been completely syn-
thesized. We thus examined a possible posttranslational trans-
location mechanism of UGT1A6DN240. For this purpose,
translation of UGT1A6DN240 mRNA was completed in a
rabbit reticulocyte lysate and then further polypeptide chain
elongation was blocked by cycloheximide prior to addition
of microsomal membranes. The results clearly showed that
as in the cotranslational mode (see Fig. 1D, compare lanes d
and b), UGT1A6DN240 was eﬃciently translocated and gly-
cosylated posttranslationally, as evidenced by the presence of
slower migrating band compared to its counterpart expressed
in the absence of microsomes (see Fig. 1D, compare lanes f
to b). In the case of UGT1A6DN240DTMD/CT, translocation
was observed neither co- nor posttranslationally (see Fig. 1D,
compare lane a to c and e). Altogether, these data indicated
that the UGT1A6 stop transfer sequence can act as a post-
translational targeting and translocation signal.3.3. The stop transfer sequence of UGT1A6 functions as an ER
targeting signal in mammalian cells
To determine whether the TMD/CT domain of UGT1A6 is
able to address and translocate upstream domain into the ER
Fig. 1. The UGT1A6 C-terminal stop transfer sequence targets and translocates the upstream ﬂanking region into the ER. (A) Schematic
representation of full-length and truncated UGT1A6 constructs. The N-glycosylation site at position 345 is shown as branched symbol. (B) In vitro
transcription and translation of UGT1A6DN240DTMD/CT and UGT1A6DN240 in the absence (lanes a and f) or presence of microsomal
membranes (all other lanes). Microsomal membranes were alkaline extracted and fractionated into membrane pellet (P, lanes c and h) and
supernatant (S, lanes d and i). Sensitivity to EndoH was analyzed in microsomal fraction (lanes e and j). (C) Western blot analysis of wild-type
UGT1A6, Asn293Gly and Asn345Gly mutants treated or not with EndoH. (D) Posttranslational targeting and translocation. mRNAs encoding for
UGT1A6DN240DTMD/CT and UGT1A6DN240 were translated in the absence (lanes a and b) or presence of microsomal membranes
(Cotranslationally Co, lanes c and d) and (Posttranslationally Post, lanes e and f).
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linked glycosylation sites was used as a reporter allowing
glycosylation to be used as a marker for ER targeting and
translocation [9]. DPSCD4-TMD/CT construct encoding the
UGT1A6 TMD/CT domain appended to the C-terminus of
CD4 protein lacking both its N-terminal signal peptide and
C-terminal anchoring domain sequences was generated (see
Fig. 2A). Immunoblot analysis of DPSCD4-TMD/CT protein
expressed in HeLa cells, showed two bands of about 54 and
50 kDa corresponding to expected size of glycosylated and
unglycosylated forms of the chimeric protein (see Fig. 2B, laneb), suggesting that about 75% of expressed protein was glycos-
ylated. In agreement, PGNaseF treatment converted the
54 kDa polypeptide (major band) to a 50 kDa band, corre-
sponding to the expected size of the unglycosylated fusion pro-
tein (see Fig. 2B, lane c). Similarly, expression of CD4-TMD/
CT protein (including CD4 N-terminal ER targeting signal
peptide) produced a polypeptide of 54 kDa which was con-
verted to a 50 kDa band after PGNaseF treatment (see
Fig. 2B, compare lane d to e). In contrast, expression
DPSCD4-DTM (CD4 deleted from both N-terminal signal
peptide and C-terminal anchoring domain) resulted in a poly-
Fig. 2. The stop transfer sequence of human UGT1A6 addresses and translocates the CD4 lumenal domain into the ER. (A) Schematic
representation of CD4-TMD/CT, DPSCD4-TMD/CT and DPSCD4DTM constructs. The two N-glycosylation sites at positions 296 and 325 were
shown as branched symbols. (B) Expression of chimeric proteins was analyzed by SDS–PAGE and detected by Western blot using polyclonal anti-
CD4 antibodies (60 lg of proteins were loaded in each line). (C) Cells expressing CD4 chimeric proteins were analyzed by immunoﬂuorescence
microscopy. Cells were ﬁxed with paraformaldehyde, permeabilized with Triton X-100, 0.1% (w/v) and stained with FITC-conjugated anti-CD4
antibodies. Cells were also stained for calnexin as ER marker using rhodamine-conjugated secondary antibodies. Merge corresponds to
colocalization (yellow) of the chimeric protein with the ER marker. Fluorescence microscopy was performed using a Zeiss microscope with a 100·
objective.
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treatment (see Fig. 2B, compare lane f to g) indicating that it
was not translocated into the ER. These results showed that
UGT1A6 TMD/CT was able to target and translocate the
CD4 lumenal domain into the ER.
To ascertain the intracellular localization of the DPSCD4-
TMD/CT chimeric protein, immunoﬂuorescence analyses were
carried out using monoclonal FITC-conjugated anti-CD4 anti-
bodies. Interestingly, analysis of Triton X-100-permeabilized
cells showed a reticular staining pattern characteristic of theER localization of DPSCD4-TMD/CT protein (see Fig. 2C).
Together, these data showed that the UGT1A6 TMD/CT do-
main was able to target and translocate upstream domain into
the ER.
3.4. UGT1A6 stop transfer is critical for enzyme activity
To gain insights into the role of the stop transfer sequence in
the enzyme function of UGT1A6, we expressed wild-type and
UGT1A6 mutants deleted from CT or from TMD/CT do-
mains in the yeast P. pastoris as described [6]. Immunoblot
Fig. 3. Expression and activity of wild-type and mutant UGT1A6
expressed in P. pastoris. (A) Immunoblot analysis. 60 lg of membrane
fraction from recombinant yeast cells were loaded on each line and
probed with anti-UGT antibodies. (B) Thin layer chromatography
analysis of glucuronidation activity of wild-type and mutant UGT1A6
towards 1-naphthol (lanes b, e and h) and tetrachlorocatechol (lanes c,
f and i). Lanes a, d and g are controls where aglycones were omitted.
The arrow indicates the position of the glucuronides.
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were expressed and associated to the membrane fraction of re-
combinant yeast cells (see Fig. 3A). Evaluation of the enzyme
activity towards 1-naphthol and tetrachlorocatechol as refer-
ence substrates indicated that UGT1A6 deleted from the CT
domain exhibited severely impaired enzyme activity. The activ-
ity was 0.04 and 0.03 pmole min1 mg1, respectively, after
normalization to the amount of expressed protein, compared
to 1.95 and 1.69 pmole min1 mg1, respectively, for wild-type
enzyme (see Fig. 3B). No glucuronidation activity could be de-
tected when UGT1A6 was deleted from TMD/CT domain
(UGT1A6DTMD/CT).4. Discussion
The most striking ﬁnding of this study was that the stop
transfer sequence, besides its ability to anchor the protein into
the ER membranes, functions as a signal sequence able to tar-
get and to translocate the upstream lumenal domain of
UGT1A6 into the ER. Indeed, we showed that UG-
T1A6DN240 was targeted and inserted into the ER micro-
somal membranes upon in vitro expression. Moreover, thispolypeptide was glycosylated indicating that upstream ﬂanking
region to the TMD was translocated across the membranes
and acquired a lumenal orientation. In contrast, the same
polypeptide missing the C-terminal stop transfer sequence
completely lost its ability to associate with ER membranes
and to be glycosylated. Furthermore, the signal activity of
the stop transfer sequence was demonstrated in HeLa cells
by its ability to target and translocate the CD4 lumenal do-
main into the ER, although translocation was more eﬃcient
in the presence of its own N-terminal signal peptide. These re-
sults provide evidence that the stop transfer sequence was able
to target and integrate the preceding polypeptide into the ER
membranes both in vitro and in mammalian cells. Accord-
ingly, the stop transfer sequence of the IgM heavy chain [11]
was shown to initiate domain translocation when placed at
an internal position. Similarly, the seventh transmembrane
segment of band 3 of the erythrocyte anion exchanger [12]
has been shown to initiate translocation process of ﬂanking re-
gions. Signal anchors, at both N- and C-terminal positions,
can act as ER targeting and retention signal, as shown for
rat cytochrome b5 [13] and yeast UBC6 transmembrane pro-
teins [14]. However, due to the very C-terminus position of
the anchoring domain of UGT1A6, as in the case of UBC6
and tail-anchored proteins, the polypeptide should be targeted
to the membranes after the synthesis has been completed [15].
In agreement, we showed that UGT1A6DN240 polypeptide
expressed in vitro was eﬃciently targeted and inserted into
the membrane posttranslationally. Similarly, a posttransla-
tional mode of insertion was demonstrated in the case of
tail-anchored proteins, Bcl-2 proto-oncogenic [8] and syna-
ptobrevin [16]. Our results suggested that the N-terminal signal
peptide and a C-terminal signal sequence can cooperate to gen-
erate the transmembrane topology of UGT proteins. Interest-
ingly, the membrane-bound form of the PrP protein has been
described to contain both a N-terminal signal peptide together
with a C-terminal TMD acting as signal sequence posttransla-
tionally [17]. It is reasonable to propose that the topology of
UGTs may result similarly from the utilization of several sig-
nal sequences. The importance of the stop transfer sequence
in UGT1A6 function was further demonstrated by the expres-
sion of UGT1A6 enzyme lacking CT or TMD/CT sequences.
Indeed, these deletions led to UGT1A6 with severely impaired
activity, suggesting the functional importance of the stop
transfer sequence in the biogenesis of active UGT1A6 enzyme.
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